Brian Piekos - Kalvista Pharmaceuticals Chief Officer

All Insiders . USA . 
Stock . Kalvista Pharmaceuticals . Stakeholders . Insider . Brian Piekos
KALV Stock  USD 10.07  0.08  0.79%   

Executive

Brian Piekos is Chief Officer of Kalvista Pharmaceuticals
Age 49
Address 55 Cambridge Parkway, Cambridge, MA, United States, 02142
Phone857 999 0075
Webhttps://www.kalvista.com

Brian Piekos Latest Insider Activity

Tracking and analyzing the buying and selling activities of Brian Piekos against Kalvista Pharmaceuticals stock is an integral part of due diligence when investing in Kalvista Pharmaceuticals. Brian Piekos insider activity provides valuable insight into whether Kalvista Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Kalvista Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Kalvista Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
 
Brian Piekos few days ago
Acquisition by Brian Piekos of 100000 shares of Kalvista Pharmaceuticals at 11.87 subject to Rule 16b-3

Kalvista Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.5394) % which means that it has lost $0.5394 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9084) %, meaning that it created substantial loss on money invested by shareholders. Kalvista Pharmaceuticals' management efficiency ratios could be used to measure how well Kalvista Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Kalvista Pharmaceuticals' Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 0.16 in 2024, whereas Return On Tangible Assets are likely to drop (1.09) in 2024. At this time, Kalvista Pharmaceuticals' Non Current Assets Total are fairly stable compared to the past year. Non Currrent Assets Other is likely to climb to about 1 M in 2024, whereas Other Current Assets are likely to drop slightly above 1 M in 2024.
Kalvista Pharmaceuticals currently holds 7.32 M in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Kalvista Pharmaceuticals has a current ratio of 17.16, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Kalvista Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Shan WuViridian Therapeutics
N/A
Matt CravetsGossamer Bio
N/A
Timothy LowingerMersana Therapeutics
60
MBA MDReplimune Group
58
MD MBAViridian Therapeutics
59
Marc MDEdgewise Therapeutics
67
Seth HarmonViridian Therapeutics
44
Lisa NolanGossamer Bio
62
Steven JDCytokinetics
65
Emily HillReplimune Group
44
Ashish MBADyne Therapeutics
N/A
John JDEdgewise Therapeutics
60
Steven ClosterSyndax Pharmaceuticals
N/A
Margaux BennettKronos Bio
N/A
Robert SmithGossamer Bio
55
Christopher SarchiReplimune Group
55
Alan MDCrinetics Pharmaceuticals
61
Diane WeiserCytokinetics
N/A
Brad FellCogent Biosciences
N/A
Melissa MannoViridian Therapeutics
N/A
Mary FentonCullinan Oncology LLC
60
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks KVD824, an oral product candidate for the treatment of HAE and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. Kalvista Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 105 people. Kalvista Pharmaceuticals (KALV) is traded on NASDAQ Exchange in USA. It is located in 55 Cambridge Parkway, Cambridge, MA, United States, 02142 and employs 150 people. Kalvista Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Return On Equity-0.91
Return On Asset-0.54

Kalvista Pharmaceuticals Leadership Team

Elected by the shareholders, the Kalvista Pharmaceuticals' board of directors comprises two types of representatives: Kalvista Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kalvista. The board's role is to monitor Kalvista Pharmaceuticals' management team and ensure that shareholders' interests are well served. Kalvista Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kalvista Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Jarrod Aldom, Vice Communications
Nicole Sweeny, Chief Officer
Ryan Baker, Head Relations
Benjamin Palleiko, Chief President
Brian Piekos, Chief Officer
John McKune, VP Fin
Thomas MBA, CEO Director
Michael PharmD, Senior Development
Christopher Yea, Chief Development Officer
MD MBA, Chief Officer
Stephen Donnelly, Director Secretary
Rachel Morten, Senior QA
Edward Feener, Chief Scientific Officer
Brian JD, General Counsel

Kalvista Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kalvista Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.91
Return On Asset-0.54
Current Valuation331.52 M
Shares Outstanding49.22 M
Shares Owned By Insiders1.34 %
Shares Owned By Institutions98.66 %
Number Of Shares Shorted6.87 M
Price To Earning(2.82) X
Price To Book2.89 X
Price To Sales107.42 X

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Kalvista Stock Analysis

When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY